No more than 15 authors can be listed.Please ensure the authors are listed in the right order.If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.
Allergic bronchopulmonary aspergillosis (ABPA) is an immune response to Aspergillus fumigatus, typically occurring in patients with asthma or cystic fibrosis. It manifests with wheezing, infiltrates, eosinophilia, and mucus plugs. ABPA affects around 1–15% of cystic fibrosis patients, often in individuals aged 25–35 years, with equal gender distribution. Despite its significance, ABPA is frequently misdiagnosed, leading to worse outcomes. Prompt and accurate diagnosis is crucial, especially in resource-limited settings like Indonesia.
A forty-two-year-old man presented with shortness of breath for one year, worsening two days before admission, aggravated by minimal activity and accompanied by productive cough. He had a history of pulmonary tuberculosis in 2022. He had been hospitalized three times with similar complaints and was initially diagnosed with community-acquired pneumonia (CAP) and chronic obstructive pulmonary disease (COPD). Despite treatment with antibiotics and bronchodilators, his condition did not improve. Examination revealed extensive wheezing, and imaging showed infiltrates and bronchiectasis. Blood tests showed eosinophilia (1272/µL), positive Aspergillus IgG, and growth of Aspergillus fumigatus in sputum culture. Total IgE was 82.95 (normal <120), and the Xpert MTB/RIF assay was negative. The patient was treated with itraconazole and prednisolone, with improvement within 7 days; therapy was continued for 8 and 12 weeks, respectively.
ABPA diagnostic criteria have evolved from Rosenberg-Patterson to ISHAM and Asano criteria. The patient met primary and secondary criteria under Rosenberg-Patterson, minor criteria under ISHAM, and 6/10 Asano criteria, including asthma-like symptoms, eosinophilia (≥500 cells/mm³), positive IgG/precipitins, fungal growth in sputum or BAL, central bronchiectasis, and high-attenuation mucus on CT. These findings confirm ABPA. Treatment with glucocorticoids and itraconazole reduced hospital stay to 7 days.